• Phio Pharmaceuticals widened net loss to $4 million, or $0.34 per share, for three months ended March 31, 2026.
• Research and development expense more than tripled to $2.8 million, driven by clinical trial, CMC, and toxicology spending tied to PH-762.
• General and administrative costs climbed 39% to $1.4 million on higher employee-related costs, investor outreach, and professional fees.
• Cash and cash equivalents fell to about $17 million as of March 31 from about $21 million at Dec. 31; April ATM agreement allows up to $6.36 million in common-stock sales.
• Phase 1b dose-escalation trial for lead candidate PH-762 completed with final data under analysis; FDA submission seeking guidance on next clinical steps targeted for second quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phio Pharmaceuticals Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202605071605NEWSFILECNPR____20260507_296434_1) on May 07, 2026, and is solely responsible for the information contained therein.